Blog
19 July 2017
Pre-Screening for Episodic Memory Deficits To Enrich Recruitment in Alzheimer’s Disease Trials
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
A key challenge of clinical trials is identifying participants that meet the screening criteria for both biomarker and cognitive deficits.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive.
Scores on the CANTAB Paired Associates Learning (PAL) task of episodic memory correlate with AD biomarkers (Barnett 2016, Nathan 2017) and have the potential to enrich samples for biomarker positive participants (Doherty 2016, Abbott 2017).
Here we evaluate the use of an online pre-screening instrument to predict deficits in commonly used cognitive screening tasks; RBANS delayed memory index, list learning and total score, Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB), and Mini-Mental State Examination (MMSE).
Tags : alzheimer's disease | patient recruitment | clinical trials | cantab | cognitive testing | brain health
Rosemary Abbott, PhD
Principal Statistical Analyst
